FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves
Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...
Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has ...
Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.
Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
Jefferies analyst Roger Song has maintained their bullish stance on NVAX stock, giving a Buy rating on October 10. Roger Song has given his Buy rating due to a combination of factors that, despite ...
On Friday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.53 which represents a decrease of $-0.37 or -2.87% from the prior close of $12.9. The stock opened at $12.72 and touched a low ...
The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback